Copeptin and Arginine Vasopressin Concentrations in Critically Ill Patients

Jochberger, Stefan; Morgenthaler, Nils G.; Mayr, Viktoria D.; Luckner, Günter; Wenzel, Volker; Ulmer, Hanno; Schwarz, S.; Hasibeder, Walter; Friesenecker, Barbara; Dünser, Martin W.

doi:10.1210/jc.2005-2830

Cited by 136 publications

(139 citation statements)

References 28 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Similarly, the current authors evaluated the same biomarkers as in CAP, which were all higher in nonsurvivors compared with survivors and had a similar accuracy for the prediction of death to the APACHE II score [107,108,115,[124][125][126].…”

Section: Biomarkers For Prognostic Assessment In Sepsismentioning

confidence: 87%

Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators

Christ‐Crain¹,

Müller²

2007

European Respiratory Journal

221

149

View full text Add to dashboard Cite

Used appropriately, biomarkers improve the assessment of respiratory tract infections and sepsis. Most prominently, circulating procalcitonin levels increase by a factor of several tens of thousands during sepsis. Using a sensitive assay, procalcitonin safely and markedly reduces antibiotic usage in respiratory tract infections and nonbacterial meningitis. Procalcitonin is the protopye of hormokine mediators. The term ''hormokine'' encompasses the cytokine-like behaviour of hormones during inflammation and infections. The concept is based on a ubiquitous expression of calcitonin peptides during sepsis. Adrenomedullin, another member of the calcitonin peptide superfamily, was shown to complement and improve the current prognostic assessment in lower respiratory tract infections. Other peptides share some features of hormokines, e.g. natriuretic peptide and copeptin. Hormokines are not only biomarkers of infection but are also pivotal inflammatory mediators. Like all mediators, their role during systemic infections is basically beneficial, possibly to combat invading microbes. However, at increased levels they can become harmful for their host. Multiple mechanisms of action were proposed. In several animal models the modulation and neutralisation of hormokines during infection was shown to improve survival, and thus might open new treatment options for severe infections, especially of the respiratory tract.

show abstract

Section: Biomarkers For Prognostic Assessment In Sepsismentioning

confidence: 87%

Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators

Christ‐Crain¹,

Müller²

2007

European Respiratory Journal

221

149

View full text Add to dashboard Cite

show abstract

“…In addition to the time wasting analytical procedures (12-24 hours) needed to measure AVP also a careful sample handling, sample extraction is needed and an addition of protease inhibitors [22,23].…”

Section: Methodsmentioning

confidence: 99%

The Clinical Value of Copeptin in Acute Coronary Syndrome

Aborehab¹

2013

J Clin Exp Cardiolog

View full text Add to dashboard Cite

Abstract(1) The introduction of a novel immunoassay measuring copeptin, the c-terminal part of the vasopressin prohormone provided a unique window in common medical disorder. We examined the ability of copeptin in combination with cardiac troponin-I (cTn-I) in diagnosis of AMI, the differentiation between AMI and UA and finally evaluate the ability of copeptin in enhancing sensitivity of cTn-I at early hours of admission in emergency department.(2) This study was carried on 50 subjects; they were divided into 33 patients with AMI and 17 patients with UA. Concentrations of copeptin, cTn-I and CK-MB were determined in their sera.(3) In AMI group, the mean serum level of copeptin was highly significant in three hours than admission time and six hours. The mean serum level of cTn-I was highly significant in six hours than the admission time and three hours. The sensitivity and specificity of copeptin and cTn-I combination were 100% and 100% at the admission time versus 72.7% and 82.4% with cTn-I alone also versus 97% and 94.1% with combination of cTn-I and CK-MB. The AUC of the combination of copeptin and cTn-I was 1 which was significantly higher than the AUC of cTn-I alone 0.81 and the AUC of combination of cTn-I and CK-MB 0.92 (4) Copeptin as a single marker has diagnostic value being superior to cTn-I within the first three hours after acute chest pain. Dual marker strategy combining cTn-I and copeptin show incremental value in the early rule out of AMI.

show abstract

“…The study group consisted mostly of men, similarly to studies by other authors, while registries indicate an increasing incidence and prevalence of HF in women [27]. In the study by Maedy et al [28], measurements of HF biomarkers at 3 months after hospital discharge had an additional prognostic value . In our study, last measurement of the study parameters were performed at discharge.…”

Section: (37)mentioning

confidence: 75%